Jim Cramer on Moderna, Inc. (MRNA): ‘The Numbers Here Are Staggering, Staggeringly Bad’
Jim Cramer, host of Mad Money, recently discussed the current state of the market and also discussed both the leading and ...
STAT7h
Want to start a fight among virus experts? Ask about HIV’s new name
Many new names sounded as if they’d been cooked up by a medieval monk. HIV-1 would henceforth be known as Lentivirus ...
Moderna (NASDAQ:MRNA) Shares Down 8.9% After Analyst Downgrade
Moderna, Inc. (NASDAQ:MRNA – Get Free Report) fell 8.9% on Wednesday after UBS Group lowered their price target on the stock from $108.00 to $96.00. UBS Group currently has a buy rating on the stock.